Pyrazolo[1,5-a]pyrimidine scaffold-based small molecules: From bench to FDA-approved TRK kinase inhibitors (Part 1)

The pyrazolo[1,5-a]pyrimidine scaffold has emerged as a privileged structure in medicinal chemistry, particularly in designing kinase-targeted therapeutics, such as tropomyosin receptor kinase (TRK) inhibitors, for targeted cancer therapy. This review provides a critical analysis of small molecules bearing this heterocyclic motif, focusing on their chemical evolution, structure-activity relationship (SAR)- driven optimization, mechanistic insights into TRK inhibition, and the translational journey of these compounds from preclinical studies to FDA-approved drugs, such as Larotrectinib. The review highlights the strategic chemical modifications that improved selectivity, pharmacokinetics, and safety profiles of TRK inhibitors. Additionally, it outlines the evolution of kinase inhibitor design strategies leveraging this scaffold and discusses current challenges and future directions in optimizing these compounds for broader clinical applications. This work aims to serve as a foundation for ongoing drug discovery efforts utilizing the pyrazolo[1,5-a]pyrimidine core in oncogenic kinase targeting. Collectively, this work underscores the significance of the pyrazolo[1,5-a]pyrimidine scaffold as a privileged chemotype and sets the stage for the rational development of next-generation TRK inhibitors with enhanced clinical utility.